A Novel Multimodal Approach to Promote Motor Recovery and Plasticity After Stroke

November 10, 2026 updated by: Amit Sethi, University of Utah

Upper extremity (UE) paresis or weakness is one of the most frequent impairments after stroke. Despite intense rehabilitation, motor and functional recovery of patients with severe hand impairments is poor. Hence, there is a need for more effective treatments to enhance motor function in patients with severe hand impairments after stroke. Adaptive functional electrical stimulation (FES) appears to be a promising treatment and has the potential to facilitate active movement in individuals with severe impairments post-stroke. In addition, transcranial random noise stimulation (trns) is a widely studied, non-invasive and safe method to enhance the corticomotor excitability in individuals with chronic stroke. However, the effect of combining trns and adaptive FES in patients with severe hand impairments has not been investigated. Therefore, the purpose of this study is to investigate whether combining trns with FES will enhance hand function in individuals with chronic stroke than FES alone. The investigators predict that combining trns with FES will significantly enhance hand function than FES alone.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The primary purpose of this study was to investigate whether combining transcranial random noise stimulation with functional electrical stimulation-facilitated task practice will enhance hand function in individuals with severe paresis post-stroke than functional electrical stimulation alone.

The study is an experimental randomized study comparing the effects of transcranial random noise stimulation with functional electrical stimulation to functional electrical stimulation alone on recovery of function in the more-affected hand in individuals with chronic stroke.

Participants were randomized to receive transcranial random noise stimulation and functional electrical stimulation-facilitated task practice or sham-transcranial random noise stimulation and functional electrical stimulation-facilitated task practice.

Participants received 18 treatment sessions over 6 weeks (3 times/week for 6-8 weeks).

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
78

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Utah
      • Salt Lake City, Utah, United States, 84112
        • Not yet recruiting
        • University of Utah
      • Salt Lake City, Utah, United States, 84108
        • Recruiting
        • University of Utah
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

40 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

Female and male subjects are eligible for inclusion only if all of the following criteria are met:

  1. Age between 40-85 years
  2. Diagnosis of first-ever subcortical stroke (single cerebrovascular accident)
  3. Stroke onset of at least six months prior to the time of participation
  4. Limited functional wrist and finger flexion and extension, as indicated between 5º-20º active movement
  5. Cognitive skills to actively participate, as indicated by scores of ≥ 24 on the Mini-Mental Status Examina-tion
  6. English speaking

Exclusion Criteria:

A subject is not eligible for inclusion if any of the following criteria apply:

  1. Presence of severe aphasia preventing the ability to follow 1-step directions at least 80% of the time
  2. Excessive spasticity of the wrist and finger muscles, defined as a Modified Ashworth Score >2
  3. Diagnosis of neurological disorders other than stroke
  4. History of recent seizure or epilepsy while taking anticonvulsants
  5. Orthopedic/musculoskeletal conditions (e.g., arthritis) affecting the upper extremity
  6. Presence of metallic implants in the head or neck
  7. Currently or planning to become pregnant
  8. Difficulty maintaining alertness or remaining still
  9. Ferromagnetic metallic implants, pacemakers, other implanted devices, or ventilators (for MRI)
  10. Bodyweight > 300 lbs due to MRI scanner dimensions (for subjects also undergoing MRI)
  11. Psychiatric diagnosis according to the criteria of the Diagnostic and Statistical Manual of Mental Disorder, Fifth Edition (DSM-V), or who are on psychotropic medication
  12. Participation in concurrent occupational therapy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Sham Comparator: sham-tRNS and FES-assisted task-specific practice

Participants will receive the intervention 3x/week for 6-8 weeks for a total of 18 intervention sessions. Participants will receive sham-tRNS during the FES-assisted task-specific practice.
Device: FES (Functional Electrical Stimulation)-assisted task-specific practice

The FES-assisted task-specific practice will focus on restituting the movement components composing functional tasks. We will use the principles of motor learning with FES-assisted task-specific practice. Based on motor learning principles, our intervention will include 1) movement practice as close to normative as possible, 2) a high number of repetitions, 3) attention to the motor task, and 4) training specificity.

Device: Sham-tRNS (Transcranial Random Noise Stimulation)

Individuals in this group will receive sham-tRNS via the same electrode configuration as the tRNS. The stimulation will gradually ramp up for 30 seconds and then fade away for the rest of the intervention session.
Experimental: tRNS and FES-assisted task-specific practice

Participants will receive the intervention 3x/week for 6-8 weeks for a total of 18 intervention sessions. Participants will receive tRNS during the FES-assisted task-specific practice.
Device: FES (Functional Electrical Stimulation)-assisted task-specific practice

The FES-assisted task-specific practice will focus on restituting the movement components composing functional tasks. We will use the principles of motor learning with FES-assisted task-specific practice. Based on motor learning principles, our intervention will include 1) movement practice as close to normative as possible, 2) a high number of repetitions, 3) attention to the motor task, and 4) training specificity.

Device: tRNS (Transcranial Random Noise Stimulation)

Individuals in this group will receive tRNS at 2 mA intensity between 101-640 Hz. The current will be gradually ramped up for and down for the first and last 30 seconds of the stimulation.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Upper Extremity Fugl-Meyer Scale
Time Frame: 6-9 weeks post-intervention

Changes in Upper Extremity Fugl-Meyer between the experimental (tRNS and FES-assisted task-specific practice) and control (sham-tRNS and FES-assisted task-specific practice) conditions. This scale measures voluntary motor control of the paretic upper extremity (UE) using a 3-point ordinal scale where 0=cannot perform, 1=performs partially, and 2=performs fully. The total possible score ranges from 0-66 with higher scores indicating a better voluntary motor control of the paretic UE.
6-9 weeks post-intervention
Stroke Impact Scale - Hand Function Score
Time Frame: 6-9 weeks post-intervention

Changes in Stroke Impact Scale - Hand Function Score between the experimental (tRNS and FES-assisted task-specific practice) and control (sham-tRNS and FES-assisted task-specific practice) conditions. Participants report paretic upper extremity (UE) use in five commonly performed daily tasks (e.g., carry a bag of groceries) using a 5-point ordinal scale, which ranges from 0-5, where 0=cannot use paretic and 5=not difficult at all to use paretic UE. The total score ranges from 0-25 with higher scores indicating better UE function.
6-9 weeks post-intervention
Transcranial Magnetic stimulation-induced motor evoked potential
Time Frame: 6-9 weeks post-intervention

Changes in cortical motor evoked potentials (MEPs) between the experimental (tRNS and FES-assisted task-specific practice) and control (sham-tRNS and FES-assisted task-specific practice) conditions. MEPs will be obtained by placing a transcranial magnetic stimulation (TMS) coil over the hand knob of the ipsilesional primary motor cortex. TMS-induced MEP amplitude will be obtained by averaging peak to peak amplitudes of 20 MEPs from the flexor carpii radials and/or extensor digitorum communis muscles. Higher values of MEP indicate greater corticospinal excitability.
6-9 weeks post-intervention

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Upper Extremity Fugl-Meyer Scale
Time Frame: 12-14 weeks post intervention

Changes in Upper Extremity Fugl-Meyer between the experimental (tRNS and FES-assisted task-specific practice) and control (sham-tRNS and FES-assisted task-specific practice) conditions. This scale measures voluntary motor control of the paretic upper extremity (UE) using a 3-point ordinal scale where 0=cannot perform, 1=performs partially, and 2=performs fully. The total possible score ranges from 0-66 with higher scores indicating a better voluntary motor control of the paretic UE.
12-14 weeks post intervention
Stroke Impact Scale - Hand Function Score
Time Frame: 12-14 weeks post intervention

Changes in Stroke Impact Scale - Hand Function Score between the experimental (tRNS and FES-assisted task-specific practice) and control (sham-tRNS and FES-assisted task-specific practice) conditions. Participants report paretic upper extremity (UE) use in five commonly performed daily tasks (e.g., carry a bag of groceries) using a 5-point ordinal scale, which ranges from 0-5, where 0=cannot use paretic and 5=not difficult at all to use paretic UE. The total score ranges from 0-25 with higher scores indicating better UE function.
12-14 weeks post intervention
Transcranial Magnetic stimulation-induced motor evoked potential
Time Frame: 12-14 weeks post intervention

Changes in cortical motor evoked potentials (MEPs) between the experimental (tRNS and FES-assisted task-specific practice) and control (sham-tRNS and FES-assisted task-specific practice) conditions. MEPs will be obtained by placing a transcranial magnetic stimulation (TMS) coil over the hand knob of the ipsilesional primary motor cortex. TMS-induced MEP amplitude will be obtained by averaging peak to peak amplitudes of 20 MEPs from the flexor carpii radials and/or extensor digitorum communis muscles. Higher values of MEP indicate greater corticospinal excitability.
12-14 weeks post intervention

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Grip Strength of the paretic hand
Time Frame: 6-9 weeks Post-intervention

Changes in Grip Strength between the experimental (tRNS and FES-assisted task-specific practice) and control (sham-tRNS and FES-assisted task-specific practice) conditions. Average grip strength of the of three trials will be reported in kilograms. Higher values indicate better grip strength.
6-9 weeks Post-intervention
Grip Strength of the paretic hand
Time Frame: 12 -14 weeks Post-intervention

Changes in Grip Strength between the experimental (tRNS and FES-assisted task-specific practice) and control (sham-tRNS and FES-assisted task-specific practice) conditions. Average grip strength of the of three trials will be reported in kilograms. Higher values indicate better grip strength.
12 -14 weeks Post-intervention
Upper extremity muscle synergy
Time Frame: 6-9 weeks Post-intervention

Changes in upper extremity muscle synergy between the experimental (tRNS and FES-assisted task-specific practice) and control (sham-tRNS and FES-assisted task-specific practice) conditions. Transcranial magnetic stimulation induced motor evoked potentials of different proximal and distal upper extremity muscles are coupled using the synergy weights and activation profiles obtained with a novel Principal component-based motor evoked potential analyses. Higher values suggest better muscle synergy.
6-9 weeks Post-intervention
Upper extremity muscle synergy
Time Frame: 12-14 weeks Post-intervention

Changes in upper extremity muscle synergy between the experimental (tRNS and FES-assisted task-specific practice) and control (sham-tRNS and FES-assisted task-specific practice) conditions. Transcranial magnetic stimulation induced motor evoked potentials of different proximal and distal upper extremity muscles are coupled using the synergy weights and activation profiles obtained with a novel Principal component-based motor evoked potential analyses. Higher values suggest better muscle synergy.
12-14 weeks Post-intervention
Upper Extremity range of motion via kinematics
Time Frame: 6-9 weeks Post-intervention

Changes in Upper Extremity kinematics between the experimental (tRNS and FES-assisted task-specific practice) and control (sham-tRNS and FES-assisted task-specific practice) conditions. 3D biomechanical data will be collected using a motion capture system. We will evaluate maximum finger excursions. Higher values indicate greater finger excursion.
6-9 weeks Post-intervention
Upper Extremity range of motion via kinematics
Time Frame: 12-14 weeks Post-intervention

Changes in Upper Extremity kinematics between the experimental (tRNS and FES-assisted task-specific practice) and control (sham-tRNS and FES-assisted task-specific practice) conditions. 3D biomechanical data will be collected using a motion capture system. We will evaluate maximum finger excursions. Higher values indicate greater finger excursion.
12-14 weeks Post-intervention
Muscle strength and activation
Time Frame: 6-9 weeks Post-intervention

Changes in muscle strength and activation between the experimental (tRNS and FES-assisted task-specific practice) and control (sham-tRNS and FES-assisted task-specific practice) conditions. Muscle strength and activation testing will be performed using the triple interpolated twitch technique for the paretic wrist and hand muscles. We will test muscle strength and activation using a customized set-up with load cells for the wrist and hand. Normalized peak force/torque will be used to calculate strength and activation. Higher values indicate greater muscle strength and activation.
6-9 weeks Post-intervention
Muscle strength and activation
Time Frame: 12-14 weeks Post-intervention

Changes in muscle strength and activation between the experimental (tRNS and FES-assisted task-specific practice) and control (sham-tRNS and FES-assisted task-specific practice) conditions. Muscle strength and activation testing will be performed using the triple interpolated twitch technique for the paretic wrist and hand muscles. We will test muscle strength and activation using a customized set-up with load cells for the wrist and hand. Normalized peak force/torque will be used to calculate strength and activation. Higher values indicate greater muscle strength and activation.
12-14 weeks Post-intervention
Action Research Arm Test
Time Frame: 6-9 weeks Post-intervention

Changes in Action Research Arm Test between the experimental (tRNS and FES-assisted task-specific practice) and control (sham-tRNS and FES-assisted task-specific practice) conditions. Action Research Arm Test evaluates upper extremity (UE) functional performance using a 4-point ordinal scale on 19-items, which are divided into 4 sub-tests (grasp, grip, pinch, and gross arm movement). The total possible score ranges from 0-57 with higher scores indicating higher UE function.
6-9 weeks Post-intervention
Action Research Arm Test
Time Frame: 12-14 weeks Post-intervention

Changes in Action Research Arm Test between the experimental (tRNS and FES-assisted task-specific practice) and control (sham-tRNS and FES-assisted task-specific practice) conditions. Action Research Arm Test evaluates upper extremity (UE) functional performance using a 4-point ordinal scale on 19-items, which are divided into 4 sub-tests (grasp, grip, pinch, and gross arm movement). The total possible score ranges from 0-57 with higher scores indicating higher UE function.
12-14 weeks Post-intervention
Social role sub-scale of Assessment of Life Habits
Time Frame: 6-9 weeks Post-intervention

Changes in Social role sub-scale of Assessment of Life Habits between the experimental (tRNS and FES-assisted task-specific practice) and control (sham-tRNS and FES-assisted task-specific practice) conditions. The Social-LIFE-H assess the quality of social participation by estimating the perceived difficulty an in-dividual faces in performing a life habit and the type of assistance required to perform it. Using 40 items, the sub-scale assesses restrictions in social responsibilities, interpersonal relationships, community life, education, employment, and leisure. Each item is scored using a 10-point ordinal scale, which ranges from 0-9, where 0 = not able to perform and 9 = able to perform without difficulty with higher scores indicating better social participation. The total possible score will be reported, which is obtained by summing the scores on each item and then dividing by the number of items.
6-9 weeks Post-intervention
Social role sub-scale of Assessment of Life Habits
Time Frame: 12-14 weeks Post-intervention

Changes in Social role sub-scale of Assessment of Life Habits between the experimental (tRNS and FES-assisted task-specific practice) and control (sham-tRNS and FES-assisted task-specific practice) conditions. The Social-LIFE-H assess the quality of social participation by estimating the perceived difficulty an in-dividual faces in performing a life habit and the type of assistance required to perform it. Using 40 items, the sub-scale assesses restrictions in social responsibilities, interpersonal relationships, community life, education, employment, and leisure. Each item is scored using a 10-point ordinal scale, which ranges from 0-9, where 0 = not able to perform and 9 = able to perform without difficulty with higher scores indicating better social participation. The total possible score will be reported, which is obtained by summing the scores on each item and then dividing by the number of items.
12-14 weeks Post-intervention
Transcranial magnetic stimulation induced cervicomedullary motor evoked potential
Time Frame: 6-9 weeks Post-intervention

Changes in transcranial magnetic stimulation (TMS) induced cervicomedullary motor evoked potential (CMEP) between the experimental (tRNS and FES-assisted task-specific practice) and control (sham-tRNS and FES-assisted task-specific practice) conditions. An average peak to peak amplitudes of 20 CMEPs will be reported from the flexor carpii radials and/or extensor digitorum communis muscles. Higher values of CMEP indicate greater spinal excitability.
6-9 weeks Post-intervention
Transcranial magnetic stimulation induced cervicomedullary motor evoked potential
Time Frame: 12-14 weeks Post-intervention

Changes in transcranial magnetic stimulation (TMS) induced cervicomedullary motor evoked potential (CMEP) between the experimental (tRNS and FES-assisted task-specific practice) and control (sham-tRNS and FES-assisted task-specific practice) conditions. An average peak to peak amplitudes of 20 CMEPs will be reported from the flexor carpii radials and/or extensor digitorum communis muscles. Higher values of CMEP indicate greater spinal excitability.
12-14 weeks Post-intervention
H-reflex excitability
Time Frame: 6-8 weeks Post-intervention

Changes in H-reflex excitability (measured by H-max/M-max ratio) between the experimental (tRNS and FES-assisted task-specific practice) and control (sham-tRNS and FES-assisted task-specific practice) conditions. H- and M- recruitment curves will be mapped for the paretic flexor carpii radials muscle. Higher values indicate greater spinal excitability.
6-8 weeks Post-intervention
H-reflex excitability
Time Frame: 12 -14 weeks Post-intervention

Changes in H-reflex excitability (measured by H-max/M-max ratio) between the experimental (tRNS and FES-assisted task-specific practice) and control (sham-tRNS and FES-assisted task-specific practice) conditions. H- and M- recruitment curves will be mapped for the paretic flexor carpii radials muscle. Higher values indicate greater spinal excitability.
12 -14 weeks Post-intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Utah

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 11, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 1, 2030

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 15, 2031

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 1, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 14, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
October 22, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 12, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 10, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 00193557

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings